OncoDNA has recently signed a number of distribution agreements for its products, which include the OncoTrace and OncoSelect liquid biopsy tests.
The firm increased the number of shares it was offering after its stock price fell sharply this week.
HudsonAlpha's Greg Barsh described results from a Clinical Sequencing Exploratory Research project during the institute's ongoing Genomic Medicine Conference.
One team suggested Cas4 is required to assist the Cas1-2 complex, while the other said Cas4 helps maintain fidelity during CRISPR adaptation.
The transcription factor FOXM1 marked meningioma cases with poorer outcomes and enhanced cell proliferation, based on integrated exome, expression, and epigenetic profiles.
Streck inked a three-year agreement with Van Xuan, a distributor with customers in public hospitals, private clinics, and pharma and manufacturing labs.
The company ended 2017 with $10 million in cash and cash equivalents, and raised $40 million in a public offering in January.
It will use the funds to help expand the development and commercialization of its non-invasive genetic tests for early-stage cancer detection.
Researchers have done single-cell RNA sequencing on hundreds of Plasmodium falciparum or P. berghei isolates to track gene activity involved in infection cycles.
The companies will initially plan to acquire the required regulatory approvals in India for the Genedrive HCV ID kit.
The company will use a portion of the credit facility to fund its announced acquisition of Integrated DNA Technologies.
JP Morgan Securities and Cowen and Company are the joint book-running managers for the offering, while William Blair is the lead manager.
KeyGene and its parent firm, KeyGene NV, were named as defendants in a NuGen Technologies suit seeking to invalidate two US patents.
Last week, GenomeWeb's readers were most interested in Illumina filing a patent infringement lawsuit against Natera.
The lab, which serves hospitals in India and surrounding countries, will use Precipio's ICE COLD-PCR technology to offer blood-based mutation tests.
Ambry will offer ArcherDX's immune repertoire sequencing assays to biopharmaceutical customers.
China has been a key focus for Agena, which established a Shanghai subsidiary in 2015.
Funding will go to the West German Genome Center, the NGS Competence Center Tübingen, the Dresden-Concept Genome Center, and the Competence Center for Genomic Analysis Kiel.
Researchers from Ambry Genetics analyzed a set of DTC results sent to them for confirmation testing and found that 40 percent were false positives.
President Trump had earlier in the day said on Twitter that he was considering vetoing the bill over an immigration issue and a lack of funding for a proposed Mexican border wall.
The company attributed the decline in part to fewer orders for its Epi proColon colorectal cancer test.
The companies have been embroiled in several lawsuits in the US and in Europe, accusing each other of patent infringement.
The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.
Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.
Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.
In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.